Johnson BE - Search Results

1

Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of antiangiogenic activity.

Beaudry P, Force J, Naumov GN, Wang A, Baker CH, Ryan A, Soker S, Johnson BE, Folkman J, Heymach JV. Beaudry P, et al. Among authors: johnson be. Clin Cancer Res. 2005 May 1;11(9):3514-22. doi: 10.1158/1078-0432.CCR-04-2271. Clin Cancer Res. 2005. PMID: 15867254

2

A phase II study of weekly paclitaxel in elderly patients with advanced non-small cell lung cancer.

Fidias P, Supko JG, Martins R, Boral A, Carey R, Grossbard M, Shapiro G, Ostler P, Lucca J, Johnson BE, Skarin A, Lynch TJ. Fidias P, et al. Among authors: johnson be. Clin Cancer Res. 2001 Dec;7(12):3942-9. Clin Cancer Res. 2001. PMID: 11751486 Clinical Trial.

3

Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer.

Maulik G, Kijima T, Ma PC, Ghosh SK, Lin J, Shapiro GI, Schaefer E, Tibaldi E, Johnson BE, Salgia R. Maulik G, et al. Among authors: johnson be. Clin Cancer Res. 2002 Feb;8(2):620-7. Clin Cancer Res. 2002. PMID: 11839685

4

Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma.

Jänne PA, Taffaro ML, Salgia R, Johnson BE. Jänne PA, et al. Among authors: johnson be. Cancer Res. 2002 Sep 15;62(18):5242-7. Cancer Res. 2002. PMID: 12234991

5

Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells.

Kijima T, Maulik G, Ma PC, Tibaldi EV, Turner RE, Rollins B, Sattler M, Johnson BE, Salgia R. Kijima T, et al. Among authors: johnson be. Cancer Res. 2002 Nov 1;62(21):6304-11. Cancer Res. 2002. PMID: 12414661

6

Induction docetaxel and carboplatin followed by weekly docetaxel and carboplatin with concurrent radiotherapy, then surgery in stage III non-small cell lung cancer: a Phase I study.

Wirth LJ, Lucca J, Ostler P, Fidias P, Lynch C, Jänne PA, Herbst RS, Johnson BE, Sugarbaker DJ, Mathisen DJ, Lukanich JM, Choi NC, Berman SM, Skarin AT. Wirth LJ, et al. Among authors: johnson be. Clin Cancer Res. 2003 May;9(5):1698-704. Clin Cancer Res. 2003. PMID: 12738723 Clinical Trial.

7

c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions.

Ma PC, Kijima T, Maulik G, Fox EA, Sattler M, Griffin JD, Johnson BE, Salgia R. Ma PC, et al. Among authors: johnson be. Cancer Res. 2003 Oct 1;63(19):6272-81. Cancer Res. 2003. PMID: 14559814

8

Phase II study of imatinib in patients with small cell lung cancer.

Johnson BE, Fischer T, Fischer B, Dunlop D, Rischin D, Silberman S, Kowalski MO, Sayles D, Dimitrijevic S, Fletcher C, Hornick J, Salgia R, Le Chevalier T. Johnson BE, et al. Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):5880-7. Clin Cancer Res. 2003. PMID: 14676110 Clinical Trial.

9

Farnesyl transferase inhibitors for patients with lung cancer.

Johnson BE, Heymach JV. Johnson BE, et al. Clin Cancer Res. 2004 Jun 15;10(12 Pt 2):4254s-4257s. doi: 10.1158/1078-0432.CCR-040016. Clin Cancer Res. 2004. PMID: 15217969 Review.

10

Phase II study of the farnesyl transferase inhibitor R115777 in patients with sensitive relapse small-cell lung cancer.

Heymach JV, Johnson DH, Khuri FR, Safran H, Schlabach LL, Yunus F, DeVore RF 3rd, De Porre PM, Richards HM, Jia X, Zhang S, Johnson BE. Heymach JV, et al. Among authors: johnson be, johnson dh. Ann Oncol. 2004 Aug;15(8):1187-93. doi: 10.1093/annonc/mdh315. Ann Oncol. 2004. PMID: 15277257 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

590 results

Search Page

Filters